The biopharma sector sees soaring merger and acquisition activity in March 2025, with major deals advancing innovation in …
The biopharma sector sees soaring merger and acquisition activity in March 2025, with major deals advancing innovation in …
European regulatory reforms are accelerating approvals for novel rare disease treatments, attracting global investment and expanding patient access.
Record venture investment is driving new biotech companies in Australia to accelerate research, clinical development, and global partnerships.
Large funding rounds and strategic partnerships highlight a more focused investment environment, concentrating on companies with late stage …
A landmark multi-hundred million dollar collaboration between Takeda and BridGene Biosciences redefines biotech funding trends this week, joined …
January’s investment activity saw a wave of biotech Series funding, with Verdiva Bio, Aviceda Therapeutics, Windward Bio, and …
Atalanta Therapeutics raises $97 million in Series B funding to accelerate RNA interference therapies into Phase 1 trials, …
Despite a cautious capital environment, North American biotech companies secured nearly $2 billion in funding in January 2025, with …
As traditional VC investment remains selective, firms like Abingworth and Vie Ventures are pioneering fresh approaches—launching billion-dollar trials …
Shanghai-based Excalipoint secures rights to two preclinical T-cell engagers from Lepu Biopharma, aiming to fast-track development for solid …
Already a subscriber? Log in